Navigation Links
Cardica Announces Fiscal 2009 Second Quarter Financial Results
Date:1/29/2009

REDWOOD CITY, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today reported financial results and corporate progress for its fiscal 2009 second quarter and six months ended December 31, 2008.

"Clinical adoption of our PAS-Port(R) Proximal Anastomosis System by cardiothoracic surgeons for use in coronary artery bypass graft (CABG) procedures since FDA clearance in September has been encouraging," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "During the quarter, nearly 200 surgeons were trained to use the PAS- Port system. The PAS-Port system has been used in increasing numbers of CABG surgeries throughout the United States, including in dozens of total connector CABG cases, in which our C-Port and PAS-Port automated systems are used to connect all bypass vein grafts, eliminating the need to hand sew these vessels."

Recent Highlights and Accomplishments

-- Trained a total of 226 U.S. surgeons on the PAS-Port system since U.S. Food and Drug Administration clearance, including 196 in the fiscal 2009 second quarter alone, and a total of 384 surgeons on the C-Port(R) Distal Anastomosis Systems since product introduction;

-- Increased cumulative worldwide shipments of PAS-Port systems to over 11,500 units, with 1,827 units shipped in the fiscal 2009 second quarter; the majority of units were shipped to U.S. customers;

-- Increased cumulative worldwide shipments of C-Port systems to over 8,000 units, with 993 units shipped in the fiscal 2009 second quarter;

-- Enabled cardiothoracic surgeons to perform dozens of total connector coronary artery bypass, or C-CAB(TM), procedures for the first time in the United States, using only the C-Port and PAS-Port systems to attach bypass grafts;


'/>"/>

SOURCE Cardica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardica Announces Fiscal 2009 First Quarter Financial Results
2. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
3. Cardica to Present at Jefferies 2nd Annual Healthcare Conference
4. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
5. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
6. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
7. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
8. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5